INNOVATE Corp. Announces MediBeacon Transdermal GFR System Prix Galien USA Nomination

What Happened

• On August 18, 2026, INNOVATE Corp. (VATE) filed a Current Report on Form 8-K to announce that its MediBeacon® Transdermal GFR System has been nominated for the 2026 Prix Galien USA Best Medical Technology award. The company issued a press release with this announcement, which is attached as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: August 18, 2026 (Form 8-K Item 8.01 other events).
• Press release title: “MediBeacon® Transdermal GFR System Nominated for 2026 Prix Galien USA Best Medical Technology.”
• Exhibit: The press release is included as Exhibit 99.1 to the 8-K.
• The report was signed by Michael J. Sena, Chief Financial Officer of INNOVATE Corp.

Why It Matters

• The nomination is third‑party recognition of INNOVATE’s MediBeacon Transdermal GFR System within the medical technology community. For investors, such industry awards can increase product visibility and credibility with clinicians, partners and potential customers. While the filing does not report financial results or operational changes, the recognition could support commercial and marketing efforts as the company continues product commercialization and market access activities.